Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for a year.It causes rapid and prolonged lymphocyte depletion and consequent homeostatic reconstitution. This leads to a radically reformed lymphocyte pool with a relative increase in regulatory T cells and expansion of autoreactive T cells. The current article gives a basic information about this potential drug molecule.
Alemtuzumab is one of the newest drugs approved for Multiple Sclerosis (MS) for patients with active relapsing-remitting multiple sclerosis. It acts by targeting CD52, an antigen primarily expressed on T and B lymphocytes, resulting in their depletion and subsequent repopulation. Multiple sclerosis The pathogenesis of MS is associated with activation of autoreactive lymphocytes, which infiltrate the central nervous system (CNS) and mediate…
